{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-026247","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.082825+00:00","generated_at":"2026-06-18T22:20:59.295968+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Quoin Pharmaceuticals prices $7.0M public offering of ADSs and warrants; amends prior warrants","bullets":["Gross proceeds ~$7.0M from offering of 4.95M ADSs at $1.00/ADS and pre-funded warrants for 2.05M ADSs at $0.9999, each with common warrants.","Existing warrants from Aug 2022 amended: exercise price reduced from $5.00 to $1.10 per ADS, term extended to Feb 24, 2028.","Offering closed Feb 24, 2023; net proceeds for general corporate purposes.","Placement agents: A.G.P./Alliance Global Partners (lead), Maxim Group, Aegis Capital; fees 7% cash plus 1% expense allowance."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-026247","json":"https://secwatch.observer/filing/0001104659-23-026247.json","markdown":"https://secwatch.observer/filing/0001104659-23-026247.md","text":"https://secwatch.observer/filing/0001104659-23-026247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923026247/0001104659-23-026247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923026247/tm237968d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:20:59.295968+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f4cd67357d4a011235c95dee3f75083baa71376","claim":"Quoin Pharmaceuticals, Ltd. entered into Securities Purchase Agreement with certain investors valued at approximately $7 million (effective 2023-02-22).","evidence_excerpt":"On February 22, 2023, Quoin Pharmaceuticals Ltd. (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”), pursuant to which the Company agreed to sell, issue, and deliver, in a registered public offering (the “Offering”) of 24,750,000,000 ordinary shares represented by 4,950,000 American Depositary Shares (“ADSs”) at a purchase price of $1.00 per ADS","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923026247/0001104659-23-026247-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"approximately $7 million"},{"label":"Effective","value":"2023-02-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}